BH3 mimetics to improve cancer therapy; mechanisms and examples.

Tumor cell survival is highly dependent on the expression of certain pro-survival Bcl-2 family proteins. An attractive therapeutic approach is to inhibit these proteins using agents that mimic the Bcl-2 homology 3 (BH3) domains of the proapoptotic Bcl-2 family members, which neutralize these proteins by binding to their surface hydrophobic grooves. A number of BH3 mimetic peptides and small molecules have been described, a few of which have advanced into clinical trials. Recent studies have highlighted ABT-737, a bona fide BH3 mimetic and potent inhibitor of antiapoptotic Bcl-2 family members, as a promising anticancer agent. This review summarizes recent advances in understanding the mechanisms of action of BH3 domains and several classes of BH3 mimetics, as well as the prospects of using these agents to improve cancer therapy.

[1]  John Calvin Reed,et al.  Inhibition of anti-apoptotic Bcl-2 family proteins by natural polyphenols: new avenues for cancer chemoprevention and chemotherapy. , 2004, Current pharmaceutical design.

[2]  Michael T. Certo,et al.  Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. , 2007, The Journal of clinical investigation.

[3]  C. Brancolini,et al.  Altering protein turnover in tumor cells: new opportunities for anti-cancer therapies. , 2005, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[4]  C. Scott,et al.  The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. , 2006, Cancer cell.

[5]  F. Sinicrope,et al.  Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis Is Inhibited by Bcl-2 but Restored by the Small Molecule Bcl-2 Inhibitor, HA 14-1, in Human Colon Cancer Cells , 2004, Clinical Cancer Research.

[6]  John Calvin Reed,et al.  Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. , 2003, Journal of medicinal chemistry.

[7]  Shaomeng Wang,et al.  Reversal of cisplatin resistance with a BH3 mimetic, (−)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL , 2005, Molecular Cancer Therapeutics.

[8]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[9]  Hui Wang,et al.  Preclinical pharmacology of 2-methoxyantimycin A compounds as novel antitumor agents , 2005, Cancer Chemotherapy and Pharmacology.

[10]  S. Cory,et al.  The Bcl-2 apoptotic switch in cancer development and therapy , 2007, Oncogene.

[11]  S. Korsmeyer,et al.  Reactivation of the p53 Tumor Suppressor Pathway by a Stapled p53 Peptide , 2007 .

[12]  Wenhua Gao,et al.  Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. , 2003, Genes & development.

[13]  T. Mitchison,et al.  Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL , 2001, Nature Cell Biology.

[14]  A. Petros,et al.  Rationale for Bcl‐XL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies , 2000, Protein science : a publication of the Protein Society.

[15]  A. Letai,et al.  BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. , 2007, Cancer cell.

[16]  P. Cartron,et al.  The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death. , 2006, Cancer research.

[17]  J. An,et al.  Critical Upstream Signals of Cytochrome c Release Induced by a Novel Bcl-2 Inhibitor* , 2004, Journal of Biological Chemistry.

[18]  J. An,et al.  Overcoming the radioresistance of prostate cancer cells with a novel Bcl-2 inhibitor , 2007, Oncogene.

[19]  Shaomeng Wang,et al.  Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma. , 2005, Molecular cancer therapeutics.

[20]  R. Lock,et al.  Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. , 2007, Blood.

[21]  A. Newland,et al.  BH3‐domain mimetic compound BH3I‐2′ induces rapid damage to the inner mitochondrial membrane prior to the cytochrome c release from mitochondria , 2003, British journal of haematology.

[22]  J. Hsieh,et al.  Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies , 2006, Nature Cell Biology.

[23]  Sanjeev Banerjee,et al.  Preclinical Studies of TW-37, a New Nonpeptidic Small-Molecule Inhibitor of Bcl-2, in Diffuse Large Cell Lymphoma Xenograft Model Reveal Drug Action on Both Bcl-2 and Mcl-1 , 2007, Clinical Cancer Research.

[24]  S. Srinivasula,et al.  Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[25]  J C Reed,et al.  Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins , 2006, Cell Death and Differentiation.

[26]  D. Green,et al.  The Pathophysiology of Mitochondrial Cell Death , 2004, Science.

[27]  S. Trudel,et al.  Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. , 2007, Blood.

[28]  Philippe Juin,et al.  The first alpha helix of Bax plays a necessary role in its ligand-induced activation by the BH3-only proteins Bid and PUMA. , 2004, Molecular cell.

[29]  A. Strasser,et al.  Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia , 2007, Cell Death and Differentiation.

[30]  P. Greipp,et al.  ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells , 2007, Leukemia.

[31]  Dimitri Semizarov,et al.  Integrative Genomic Analysis of Small-Cell Lung Carcinoma Reveals Correlates of Sensitivity to Bcl-2 Antagonists and Uncovers Novel Chromosomal Gains , 2007, Molecular Cancer Research.

[32]  W. Zong,et al.  BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. , 2001, Genes & development.

[33]  S. Cory,et al.  Killing cancer cells by flipping the Bcl-2/Bax switch. , 2005, Cancer cell.

[34]  L. Hansen,et al.  Methods and biomarkers for the diagnosis and prognosis of cancer and other diseases: towards personalized medicine. , 2006, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[35]  S. Grant,et al.  Targeting multiple arms of the apoptotic regulatory machinery. , 2007, Cancer research.

[36]  S. Ray,et al.  Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitor , 2005, Apoptosis.

[37]  H. Abaan,et al.  Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. , 2006, Journal of medicinal chemistry.

[38]  John Calvin Reed,et al.  Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins. , 2003, Cancer research.

[39]  Sanjeev Banerjee,et al.  Nonpeptidic Small-Molecule Inhibitor of Bcl-2 and Bcl-XL, (−)-Gossypol, Enhances Biological Effect of Genistein Against BxPC-3 Human Pancreatic Cancer Cell Line , 2005, Pancreas.

[40]  S. Joos,et al.  The role of Bcl-2 family members in tumorigenesis. , 2004, Biochimica et biophysica acta.

[41]  Andrew D. Hamilton,et al.  Development of a Potent Bcl-xL Antagonist Based on α-Helix Mimicry , 2002 .

[42]  E. Pinard,et al.  The Mitochondrial Effects of Small Organic Ligands of BCL-2 , 2006, Journal of Biological Chemistry.

[43]  S. Korsmeyer,et al.  Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix , 2004, Science.

[44]  S. Fesik,et al.  ‘Seed’ analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737 , 2007, Oncogene.

[45]  M. Cascio,et al.  Sequence and helicity requirements for the proapoptotic activity of Bax BH3 peptides. , 2004, Molecular cancer therapeutics.

[46]  Stephen W. Fesik,et al.  Promoting apoptosis as a strategy for cancer drug discovery , 2005, Nature Reviews Cancer.

[47]  Dajun Yang,et al.  Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells. , 2003, Biochemical pharmacology.

[48]  P. Dent,et al.  Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. , 2007, Cancer research.

[49]  Scott W. Lowe,et al.  Apoptosis A Link between Cancer Genetics and Chemotherapy , 2002, Cell.

[50]  C. Sawyers.  Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics. , 2002, Cancer cell.

[51]  S. Armstrong,et al.  Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. , 2006, Cancer cell.

[52]  Maurizio Pellecchia,et al.  Rational Design and Real Time, In-Cell Detection of the Proapoptotic Activity of a Novel Compound Targeting Bcl-XL , 2004 .

[53]  Kam Y. J. Zhang,et al.  Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3 , 2001, Nature Cell Biology.

[54]  N. Munshi,et al.  A novel Bcl-2/Bcl-XL/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma , 2007, Oncogene.

[55]  R. Meadows,et al.  Structure of Bcl-xL-Bak Peptide Complex: Recognition Between Regulators of Apoptosis , 1997, Science.

[56]  Erinna F. Lee,et al.  Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family , 2007, Cell Death and Differentiation.

[57]  A. Strasser,et al.  BH3-Only Proteins—Essential Initiators of Apoptotic Cell Death , 2000, Cell.

[58]  I. Enyedy,et al.  Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. , 2001, Journal of medicinal chemistry.

[59]  Qiang Yu.  Restoring p53-mediated apoptosis in cancer cells: new opportunities for cancer therapy. , 2006, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[60]  E. Campo,et al.  The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. , 2007, Blood.

[61]  S. Dowdy,et al.  Targeting Apoptotic Pathways in Cancer Cells , 2004, Science.

[62]  John Calvin Reed.  Apoptosis-targeted therapies for cancer. , 2003, Cancer cell.

[63]  D. Schrump,et al.  Gossypol, a phytochemical with BH3-mimetic property, sensitizes cultured thoracic cancer cells to Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. , 2006, The Journal of thoracic and cardiovascular surgery.

[64]  W. D. Fairlie,et al.  (alpha/beta+alpha)-peptide antagonists of BH3 domain/Bcl-x(L) recognition: toward general strategies for foldamer-based inhibition of protein-protein interactions. , 2007, Journal of the American Chemical Society.

[65]  S. Korsmeyer,et al.  BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. , 2001, Molecular cell.

[66]  C. Tse,et al.  Bcl-2 family proteins are essential for platelet survival , 2007, Cell Death and Differentiation.

[67]  S. Trudel,et al.  The Bcl-2 Family Protein Inhibitor, ABT-737, Has Substantial Antimyeloma Activity and Shows Synergistic Effect with Dexamethasone and Melphalan , 2007, Clinical Cancer Research.

[68]  J. Baell,et al.  Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs. , 2002, Biochemical pharmacology.

[69]  T. Myers,et al.  An informatics approach identifying markers of chemosensitivity in human cancer cell lines. , 2000, Cancer research.

[70]  D. Crouch,et al.  Inactivation of MAP kinase signalling in Myc Transformed Cells and Rescue by LiCl inhibition of GSK3 , 2005, Molecular Cancer.

[71]  S. Shangary,et al.  Peptides derived from BH3 domains of Bcl-2 family members: a comparative analysis of inhibition of Bcl-2, Bcl-x(L) and Bax oligomerization, induction of cytochrome c release, and activation of cell death. , 2002, Biochemistry.

[72]  P. Ekert,et al.  Programmed Anuclear Cell Death Delimits Platelet Life Span , 2007, Cell.

[73]  C. Tse,et al.  Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. , 2007, Cancer research.

[74]  T. Tsuruo,et al.  Defects of the apoptotic pathway as therapeutic target against cancer. , 2005, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[75]  Mary K Joseph,et al.  Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. , 2007, Journal of medicinal chemistry.

[76]  L. Oliver,et al.  HA14-1, a small molecule inhibitor of Bcl-2, bypasses chemoresistance in leukaemia cells. , 2007, Leukemia research.

[77]  M. Konopleva,et al.  Concomitant Inhibition of MDM2 and Bcl-2 Protein Function Synergistically Induce Mitochondrial Apoptosis in AML , 2006, Cell cycle.

[78]  X. Wang.  The expanding role of mitochondria in apoptosis. , 2001, Genes & development.

[79]  James T. Elder,et al.  A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. , 2006, Cancer research.

[80]  M. Konopleva,et al.  Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. , 2002, Blood.

[81]  Andrew D. Hamilton,et al.  Terphenyl-Based Bak BH3 α-Helical Proteomimetics as Low-Molecular-Weight Antagonists of Bcl-xL , 2005 .

[82]  C. Hudis,et al.  Oral Gossypol in the Treatment of Patients with Refractory Metastatic Breast Cancer: A Phase I/II Clinical Trial , 2001, Breast Cancer Research and Treatment.

[83]  R. Coombes,et al.  A preliminary clinical study of gossypol in advanced human cancer , 2004, Cancer Chemotherapy and Pharmacology.

[84]  K. Griffith,et al.  (-)-gossypol inhibits growth and promotes apoptosis of human head and neck squamous cell carcinoma in vivo. , 2006, Neoplasia.

[85]  Shaomeng Wang,et al.  In vitro Effects of the BH3 Mimetic, (−)-Gossypol, on Head and Neck Squamous Cell Carcinoma Cells , 2004, Clinical Cancer Research.

[86]  R. Craig,et al.  The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to, those of Bcl-2 , 1995, The Journal of cell biology.

[87]  A. Newland,et al.  Bcl-2 Inhibitors Sensitize Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis by Uncoupling of Mitochondrial Respiration in Human Leukemic CEM Cells , 2004, Cancer Research.

[88]  A. Strasser,et al.  Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic , 2006, Proceedings of the National Academy of Sciences.

[89]  S. Shangary,et al.  Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family , 2003, Leukemia.

[90]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[91]  Erinna F. Lee,et al.  Apoptosis Initiated When BH3 Ligands Engage Multiple Bcl-2 Homologs, Not Bax or Bak , 2007, Science.

[92]  S. Korsmeyer,et al.  A stapled BID BH3 helix directly binds and activates BAX. , 2006, Molecular cell.

[93]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[94]  J. McCubrey,et al.  Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. , 2007, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[95]  Yun Dai,et al.  A Bcr/Abl-independent, Lyn-dependent Form of Imatinib Mesylate (STI-571) Resistance Is Associated with Altered Expression of Bcl-2* , 2004, Journal of Biological Chemistry.

[96]  Xiaodong Wang,et al.  Mule/ARF-BP1, a BH3-Only E3 Ubiquitin Ligase, Catalyzes the Polyubiquitination of Mcl-1 and Regulates Apoptosis , 2005, Cell.

[97]  Shaomeng Wang,et al.  Chimeric (α/β + α)-Peptide Ligands for the BH3-Recognition Cleft of Bcl-xL: Critical Role of the Molecular Scaffold in Protein Surface Recognition , 2005 .

[98]  J. Willey,et al.  Variation in transcriptional regulation of cyclin dependent kinase inhibitor p21waf1/cip1 among human bronchogenic carcinomas , 2005, Molecular Cancer.

[99]  D. Hockenbery,et al.  2-Methoxy antimycin reveals a unique mechanism for Bcl-xL inhibition , 2007, Molecular Cancer Therapeutics.

[100]  F. Mollinedo,et al.  Fas/CD95 death receptor and lipid rafts: new targets for apoptosis-directed cancer therapy. , 2006, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[101]  Q. Li,et al.  DIFFERENTIAL GROWTH INHIBITION AND INDUCTION OF APOPTOSIS BY GOSSYPOL BETWEEN HCT116 AND HCT116/BAX−/– COLORECTAL CANCER CELLS , 2007, Clinical and experimental pharmacology & physiology.

[102]  Yun Dai,et al.  The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism. , 2004, Molecular cancer therapeutics.

[103]  H. Lin,et al.  Small-molecule Bcl-2 inhibitors sensitise tumour cells to immune-mediated destruction , 2007, British Journal of Cancer.

[104]  S. Korsmeyer,et al.  Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. , 2002, Cancer cell.

[105]  John Calvin Reed,et al.  Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. , 2006, Cancer cell.

[106]  A. D. Buss,et al.  Identification of Chelerythrine as an Inhibitor of BclXL Function* , 2003, Journal of Biological Chemistry.

[107]  T. Kuwana,et al.  BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. , 2005, Molecular cell.

[108]  Brian J. Smith,et al.  Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. , 2005, Molecular cell.

[109]  Shaomeng Wang,et al.  (-)-Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-X(L)-mediated apoptosis resistance. , 2005, Molecular cancer therapeutics.

[110]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[111]  Nektarios Tavernarakis,et al.  Functional and physical interaction between Bcl‐XL and a BH3‐like domain in Beclin‐1 , 2007, The EMBO journal.

[112]  S. Korsmeyer,et al.  Cell Death Critical Control Points , 2004, Cell.

[113]  Shaomeng Wang,et al.  (-)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer. , 2005, Molecular cancer therapeutics.

[114]  S. Grant,et al.  The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells , 2003, Leukemia.

[115]  E. Haura,et al.  A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells , 2008, Cancer Chemotherapy and Pharmacology.

[116]  John Calvin Reed,et al.  Apoptosis-based therapies for hematologic malignancies. , 2005, Blood.

[117]  W. Zong,et al.  Gossypol induces Bax/Bak‐independent activation of apoptosis and cytochrome c release via a conformational change in Bcl‐2 , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.